Суббота, 03.12.2016, 01:15
Приветствуем Вас Гость | RSS | Sitemap-Forum | Sitemap-Website
Поиск по_сайту.
Главная | Карта сайта | Информеры | Магазин | | Поиск | Регистрация | Вход

Жизнь вопреки
ХПН

 
А знаете ли Вы, что:

      
Форма входа
Логин:
Пароль:
Не получается войти? Попробуйте через эту форму.
Закладки Добавить
Меню сайта

Категории
Документы для специалистов [22]
История диализа [7]
История центра [5]
Базы данных [4]
Статьи и абстракты [40]
____________________
Информация о ближайших конференциях [6]
Материалы прошедших конференций [7]
Новости науки [38]
Презентации [72]
Калькуляторы [19]
Вопросы [8]
Полемика [21]
Словари [0]

Календарь
«  Август 2008  »
ПнВтСрЧтПтСбВс
    123
45678910
11121314151617
18192021222324
25262728293031

Опрос
Если показатель гемоглобина A1c более 8% - это признак того, что Ваше лечение должно быть изменено.
Всего ответов: 161


Статистика
Rambler's Top100
Яндекс цитирования
MyMed
Кодекс этики врачей Рунета
Онлайн всего: 30
Из них Гостей: 25
Пользователей: 5

New-Den, ten_161, Лисица, Ukr, N@t@


Ваш браузер:
Версия:
Поздравляем именинников

Иван-А(37), Lorik(59), tluch(37), MalenkayaSonya(11), gordik12(54), nataliya(33), Елена57(31), Ольга_Кем(41), аташе(52), 0669496950(31)








Необходимые документы
(1) и (2)

*********** ************** *************
Главная » 2008 » Август » 21 » ureMIA

ureMIA

13:24
Сообщение, которое не оставило равнодушным. Это было в Сан-Диего в 2006 году
А вот исследование, предпринятое китайцами из Гон-Конга, исследование, которое, к сожалению,  приостановлено из-за нехватки денег.
Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients

This study has been suspended.
( Fail of applying funding )

Sponsored by: Chinese University of Hong Kong
Information provided by: Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT00390247
  Purpose

Hypothesis In peritoneal dialysis (PD) patients, malnutrition, inflammation and atherosclerotic cardiovascular disease commonly coexist. The triad has been coined the “MIA syndrome”. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-), plays a central role in the pathogenesis of the MIA syndrome. Thalidomide selectively inhibits the production of TNF- and represents a valuable anti-cytokine therapy.

Specific Aim To study the effect of thalidomide in attenuating or reversing malnutrition and systemic inflammation in PD patients.

Research Plan

  • Design: Double-blinded randomised prospective placebo control trial.
  • Setting: Renal unit of a university teaching hospital.
  • Subjects: Sixty prevalent PD patients with evidence of malnutrition.
  • Interventions: Patients will be randomised to receive either oral thalidomide 100 mg nocte or placebo.
  • Main outcome measures: Patients will be followed for 1 year. Nutritional parameters including serum albumin, subjective global assessment, malnutrition-inflammation score, normalised protein nitrogen appearance, fat-free edema-free body mass and anthropometry measurements will be monitored. Systemic inflammatory markers such as serum C-reactive protein and IL-6 will be assayed. Hospitalisation, cardiovascular events, and overall patient survival will also be compared during study period.

Expected Outcome

Nutritional parameters and markers of systemic inflammation are expected to improve with thalidomide therapy. The magnitude of improvement in nutrition, as well as patient morbidity, will be compared with placebo.

In Hong Kong, 80% of end-stage renal failure patients are treated with PD. Malnutrition, cardiovascular disease and systemic inflammatory response are all common in our clinical practice. They are major causes of patient morbidity and mortality. As a readily available anti-cytokine therapy, thalidomide may represent a valuable treatment of the MIA syndrome. The proposed study will provide important insight on the clinical benefit of thalidomide treatment in malnourished PD patients, which accounts for about one-third of our dialysis population.


Condition Intervention Phase
Peritoneal Dialysis
Malnutrition
Drug: thalidomide
Phase IV

MedlinePlus related topics:   Kidney Failure   

ChemIDplus related topics:   Thalidomide   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial

Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • Nutritional status

Secondary Outcome Measures:
  •  Change in arterial pulse wave velocity
  •  Total number of days of hospital admission during study period
  •  Composite cardiovascular end point

Estimated Enrollment:   60
Study Start Date:   January 2007
Estimated Study Completion Date:   December 2008

Show detailed description  Show Detailed Description

  Eligibility
Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • clinically stable adult patients (18 to 80 years old) on PD; and
  • evidence of malnutrition:

    1. overall subjective global assessment score  5; or
    2. malnutrition inflammation score  9; or
    3. serum albumin  35 g/L
  • written patient informed consent

Exclusion Criteria:

  • Patients who are planned to have elective living donor transplant within 6 months
  • Patients who are planned to transfer to other renal center within 6 months
  • High likelihood of early withdrawal from the study (e.g. myocardial infarction, severe or unstable coronary disease, stroke, severe liver disease within 3 months)
  • Active infection or systemic inflammatory disease.
  • Current malignant disease
  • Pregnancy or breast-feeding
  • Women of childbearing potential with unreliable birth control methods
  • Known hypersensitivity to thalidomide
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00390247

Locations
Hong Kong
Renal Unit, Department of Medicine & Therapeutics, Prince of Wales Hospital    
      Hong Kong, Hong Kong

Sponsors and Collaborators
Chinese University of Hong Kong

Investigators
Principal Investigator:     Cheuk-Chun Szeto, MD     Chinese University of Hong Kong    
  More Information

Study ID Numbers:   CRE-2006.291
First Received:   October 18, 2006
Last Updated:   April 5, 2007
ClinicalTrials.gov Identifier:   NCT00390247
Health Authority:   Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Study placed in the following topic categories:
Malnutrition
Thalidomide
Nutrition Disorders
Inflammation

Additional relevant MeSH terms:
Anti-Infective Agents
Immunologic Factors
Antineoplastic Agents
Growth Substances
Physiological Effects of Drugs
Immunosuppressive Agents
Angiogenesis Inhibitors
Pharmacologic Actions
Anti-Bacterial Agents
Pathologic Processes
Therapeutic Uses
Angiogenesis Modulating Agents
Growth Inhibitors
Leprostatic Agents

ClinicalTrials.gov processed this record on August 20, 2008
Категория: Материалы прошедших конференций | Просмотров: 1401 | Добавил: Денисов | Рейтинг: 0.0/0 | | Обсудить: на Форуме.
Ссылки на документ, для вставки на форум или к себе на страницу.
Для форума BB-Code
Ссылка
Всего комментариев: 0
Добавлять комментарии могут только зарегистрированные пользователи.
[ Регистрация | Вход ]

Гемодиализ, Диализ, Форум, Трансплантация, Нефропротекция, Жизнь вопреки Хронической Почечной Недостаточности.

[ Главная | Карта сайта | Информеры | Новости | Для пациентов | Для специалистов | FAQ (вопрос/ответ) | Форум | Чат | Блог ]
[ Новый Нефрон | Карта диализа Москвы | Обратная связь | Консультация | | Регистрация | Вход ]
Магазин
Внимание! Информация на сайте www.Dr-Denisov.ru предназначена исключительно для образовательных и научных целей. При копировании материала с сайта, ОБЯЗАТЕЛЬНА активная ссылка на сайт www.Dr-Denisov.ru.
                                            Жизнь вопреки ХПН © 2007 - 2016